Guerbet
Clinical trials sponsored by Guerbet, explained in plain language.
A pharmaceutical company specializing in contrast media and medical imaging products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New MRI dye could spot dangerous artery blockages better
Diagnosis Recruiting nowThis Phase 3 trial tests whether a new contrast agent called gadopiclenol works as well as the standard agent (Dotarem) for MRI scans to find blocked arteries in the neck, legs, or abdomen. About 315 adults with suspected vascular disease will receive both agents in random order …
Phase: PHASE3 • Sponsor: Guerbet • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
MRI dye safety under scrutiny: landmark study tracks brain effects over 5 years
Knowledge-focused Recruiting nowThis study looks at whether repeated doses of a gadolinium-based contrast agent (a dye used in MRI scans) affect motor and cognitive functions in healthy adults. About 2076 participants will receive annual imaging and undergo tests over 5 years. The goal is to compare changes in …
Phase: PHASE4 • Sponsor: Guerbet • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC